Elixir Medical Corp. aims to address the shortcomings of current drug-eluting stents, such as late stent thrombosis, dual antiplatelet therapy duration and better efficacy in more complex disease. Elixir's technology innovations include what it describes as the thinnest durable biocompatible polymer coating, an ultra-thin biodegradable polymer coating and a fully biodegradable drug eluting stent.
870 Hermosa Drive
Sunnyvale, CA 94085
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The drugmaker plans to move into Phase III development of the drug, which has now posted positive Phase II results in narcolepsy types 1 and 2.
Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.
The company announced data from patients enrolled after a protocol amendment designed to bring the study in line with non-muscle invasive bladder cancer (NMIBC) standards of care.
A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.
CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”
Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.
Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.
